Carregant...
A patent review on PD-1/PD-L1 antagonists: small molecules, peptides and macrocycles (2015–2018)
INTRODUCTION: The protein protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs. More...
Guardat en:
| Publicat a: | Expert Opin Ther Pat |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6323140/ https://ncbi.nlm.nih.gov/pubmed/30107136 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543776.2018.1512706 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|